Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lesley Tilson

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Recent developments in pricing and reimbursement of medicines in IrelandMichael Barry, Lesley Tilson
Expert Review of Pharmacoeconomics & Outcomes Research|June 16, 2010
Recent developments in pharmacoeconomic evaluation in IrelandLesley Tilson, Michael Barry
Expert Review of Pharmacoeconomics & Outcomes Research|June 16, 2010
Public drug expenditure in the Republic of IrelandMichael Barry, Cara Usher, Lesley Tilson
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2004
Pricing and reimbursement of drugs in IrelandMichael Barry, Lesley Tilson, Máirín Ryan
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 25, 2005
The potential impact of implementing a system of generic substitution on the community drug schemes in IrelandLesley Tilson, Kathleen Bennett, Michael Barry
Pharmacoeconomics|August 29, 2009
Estimating drug costs in economic evaluations in Ireland and the UK: an analysis of practice and research recommendationsDyfrig A Hughes, Lesley Tilson, Michael Drummond
Pharmacoeconomics|October 7, 2009
A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare settingLaura McCullagh, Lesley Tilson, Cathal Walsh, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 2, 2020
To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in IrelandHelen O'Donnell, Felicity Lamrock, Lesley Tilson, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 2, 2020
A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in IrelandFelicity Lamrock, Laura McCullagh, Lesley Tilson, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2004
The high cost of medicines in Ireland. Is it time to change the pricing mechanism?Lesley Tilson, Bernadette McGowan, Kathleen Bennett, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Recent developments in pricing and reimbursement of medicines in IrelandMichael Barry, Lesley Tilson
Expert Review of Pharmacoeconomics & Outcomes Research|June 16, 2010
Recent developments in pharmacoeconomic evaluation in IrelandLesley Tilson, Michael Barry
Expert Review of Pharmacoeconomics & Outcomes Research|June 16, 2010
Public drug expenditure in the Republic of IrelandMichael Barry, Cara Usher, Lesley Tilson
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2004
Pricing and reimbursement of drugs in IrelandMichael Barry, Lesley Tilson, Máirín Ryan
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 25, 2005
The potential impact of implementing a system of generic substitution on the community drug schemes in IrelandLesley Tilson, Kathleen Bennett, Michael Barry
Pharmacoeconomics|August 29, 2009
Estimating drug costs in economic evaluations in Ireland and the UK: an analysis of practice and research recommendationsDyfrig A Hughes, Lesley Tilson, Michael Drummond
Pharmacoeconomics|October 7, 2009
A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare settingLaura McCullagh, Lesley Tilson, Cathal Walsh, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 2, 2020
To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in IrelandHelen O'Donnell, Felicity Lamrock, Lesley Tilson, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 2, 2020
A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in IrelandFelicity Lamrock, Laura McCullagh, Lesley Tilson, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2004
The high cost of medicines in Ireland. Is it time to change the pricing mechanism?Lesley Tilson, Bernadette McGowan, Kathleen Bennett, et al.
Pageof 3